Comparative Pharmacology
Head-to-head clinical analysis: ATARAX versus CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATARAX versus CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
ATARAX vs CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Selective peripheral H1-receptor antagonist. Competitively inhibits histamine at the H1 receptor, preventing histamine-mediated symptoms such as pruritus, sneezing, and rhinorrhea.
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
Oral, 10 mg once daily; may be increased to 10 mg twice daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
Terminal elimination half-life is approximately 8-11 hours in healthy adults; increases to approximately 20 hours in renal impairment (CrCl <40 mL/min).
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; 10% is excreted in feces. Biliary excretion is minimal.
Category C
Category A/B
Antihistamine
Antihistamine